Skip to content
Biotechnology

OncoSil Medical Appoints Lel Smits as Non-Executive Director

OncoSil Medical Limited (ASX:OSL) 3 mins read

Pancreatic cancer treatment device company OncoSil Medical Limited (ASX:OSL) has announced the appointment of Ms. Lel Smits as a NonExecutive Director to the Board of OncoSil Medical, effective immediately. Ms. Smits brings a wealth of expertise in governance, strategy, risk oversight, and corporate communications, with a distinguished career advising over 500 ASX-listed management teams and Boards.

Ms. Smits is an award-winning entrepreneur and director, recognised as Director of the Year by Women in Finance in both 2024 and 2022. Since 2021, she has served as a Director on the Board of Australian Shareholders' Association. Her extensive career began as a finance journalist, including roles as a foreign correspondent in New York, reporting from inside the New York Stock Exchange on Wall Street.

With deep experience in the financial markets and corporate affairs, Ms. Smits has contributed significantly to entrepreneurial ventures and Boards, enhancing their governance and strategic direction. She holds formal qualifications including a Master of Arts in Journalism from the University of Technology, Sydney (UTS), a Diploma of Investor Relations from the Australasian Investor Relations Association (AIRA) and is a graduate of the Australian Institute of Company Directors’ (AICD) Company Directors Course.

Nigel Lange, CEO & Managing Director of OncoSil Medical, said:

"We are delighted to welcome Lel to the OncoSil Board. Her extensive experience across governance, strategy, and corporate affairs will be invaluable as we continue to advance our mission of delivering innovative treatments to patients globally. Her strategic insights and leadership in investor relations will undoubtedly strengthen our efforts to create value for all stakeholders."

Lel Smits stated: “I am honoured to join the Board of OncoSil Medical at such a pivotal time for the company. OncoSil’s commitment to improving patient outcomes aligns with my passion for fostering innovation and governance excellence. I look forward to utilising my extensive experience across corporate communications, media and investor relations to contribute to the company’s strategic objectives and supporting its growth journey.”

The Board of OncoSil Medical warmly welcomes Ms. Smits and looks forward to her contributions in supporting the company’s vision and objectives.

Read the full announcement here.

 


About us:

About OncoSil Medical
OncoSil Medical Limited (ASX:OSL) has developed a cancer treatment device, the OncoSil™ brachytherapy device, which is a critical component of a revolutionary brachytherapy treatment for locally advanced unresectable pancreatic cancer. This type of cancer is the 12th most common cancer in men and the 11th most common cancer in women across the globe, with some 500,000 new cases of pancreatic cancer detected every year. With pancreatic cancer typically diagnosed at a later stage, it has a poor prognosis for longterm survival.

The OncoSil™ device delivers a targeted intratumoural placement of Phosphorous-32 (32P) in the treatment of locally advanced unresectable pancreatic cancer. This occurs via injection directly into a patient’s pancreatic tumours under endoscopic ultrasound guidance and takes place in combination with gemcitabine-based chemotherapy. 

The OncoSil™ device that has already received breakthrough device designation in the European Union, United Kingdom and United States for the treatment of locally advanced unresectable pancreatic cancer in combination with chemotherapy. CE Marking has additionally been granted for the OncoSil™ device, which can be marketed in the European Union, United Kingdom.

While clinical trials involving the OncoSil™ device continue to occur, the Company is simultaneously moving to commercialise this unique medical technology. It is currently approved for sale in 30+ countries including European Union, United Kingdom, Türkiye and Israel, with initial commercial pancreatic cancer treatments using the device already undertaken in Spain, Italy and Israel.

To learn more, please visit: www.oncosil.com


Contact details:

For more information, please contact:

Mr. Nigel Lange
CEO & Managing Director
E: nigel.lange@oncosil.com
T: +49 30 300 149 3043

Mr. Christian Dal Cin
CFO & Company Secretary
E: c.dalcin@acclime.com
T: +61 3 9824 5254

Media & Investor Enquiries
Ms. Julia Maguire
The Capital Network
Media and Investor Enquiries
E: julia@thecapitalnetwork.com.au
T: +61 2 8999 3699

More from this category

  • Biotechnology
  • 13/02/2025
  • 03:14
Monash University

Stronger, safer, smarter: pioneering Zinc-based dissolvable implants for better bone repair

Monash research could transform how broken bones are treated, with the development of a special zinc-based dissolvable material that could replace the metal plates…

  • Contains:
  • Biotechnology
  • 12/02/2025
  • 11:19
BTC Health Limited (ASX:BTC)

BTC announces CFO and Company Secretary appointment

Melbourne, Australia: BTC Health (ASX: BTC) (BTC or the Company) is pleased to announce the appointment ofSalesh Balak as Chief Financial Officer and Company Secretary, effective 17 March 2025.This appointment reflects the underlying expansion of theBTC business, and the appointment of Josh Kahanovitz, current Head of Finance, into the role of Chief Operating Officer from 17 March 2025. Salesh joins BTC from Universal Biosensors Australia, where he was the Chief Financial Officer and Company Secretary for more than 18 years. He is a member of the Institute of Chartered Accountants, (CA) and Certified Practicing Accountants (CPA). BTC’s current Company Secretary,…

  • Biotechnology
  • 10/02/2025
  • 11:48
BTC Health Limited (ASX:BTC)

BTC expands distribution partnership with Arna Pharma

• License and distribution agreement forBronchitol and Aridol converted from an initial 10- year term to an indefinite license • BTC to earn royalties from sales ofBronchitol and Aridol in Singapore and Malaysia • BTC granted first right of refusal to Arna Pharma's new product pipeline Melbourne, Australia: BTC Health (ASX: BTC) (BTC or the Company) is pleased to announce that its whollyowned investee company, BTC Pharma, has amended its existing License and Distribution Agreement for the Bronchitol and Aridol products (Products) and extended its partnership with Arna Pharma, with effect from 1 February 2025. Under the terms of the…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.